Print thisExelixis Jobs in and around Worcester, MA
Company:ExelixisCurrent Opportunities (0) Location(s):210 E. Grand Ave.South San Francisco, CA Map Location 
Phone:(650) 837-7000Industry:Healthcare / Pharmaceuticals / MedicalSize:500 or more |
 |
|
Company OverviewLooking for a career at Exelixis?We are looking for people to join us as we turn our vision into reality. Commercializing truly innovative therapies requires creative approaches to the drug development process. At Exelixis, innovation is everywhere, creating a new paradigm for the biotechnology industry. A Broad and Expanding Pipeline At Exelixis, we are committed to making a meaningful impact on the lives of patients living with cancer. We are advancing an ambitious and pragmatic approach to drug development, to develop first-in-class and best-in-class therapies that will transform the treatment of cancer. We are transforming the challenges of our industry into opportunities for success by thinking larger, moving faster and charting our own course to our goal. Today we are a development-stage biotechnology company with an uncommonly rich pipeline of twelve compounds in clinical development with many more advancing to the clinic. As we look toward the future, we are building a portfolio of targeted compounds that modulate the activity of multiple disease-related pathways to achieve superior disease control and patient outcomes. Leveraging the Power of Our Platform We believe that the next generation of cancer therapies requires innovation in every part of our research, development and business organizations. At Exelixis, this means pursuing an uncommon approach to research and development, one that combines critical mass, speed, and unique approaches to create significant momentum toward our goals. With a library of more than 4 million compounds, we are able to rapidly identify high-quality leads for new drugs. Our extensive abilities in structure-based design and our approaches to pharmacodynamics and pharmacokinetics enable us to move these leads quickly forward. These capabilities are a resource that will enable us to file at least three investigational new drug applications (IND) each year for the foreseeable future. Even with an extensive and vigorous selection process to assure high-quality, we retained our speed, filing twelve INDs in the past three years. The strength and efficiency of our selection, screening and development processes provide a steady flow of promising product candidates. With so many opportunities, we believe that we have the ability to select only those compounds for which the data demonstrate clear first-in-class and best-in-class. This power is combined with a disciplined, pragmatic approach to managing our pipeline based on data and real medical need. Building the Momentum Toward Our Goal We believe our commitment to significantly invest in preclinical development provides a more solid foundation on which to build new treatments for cancer. We believe the return on this investment will come in the form of higher clinical success rates and funding and partnership terms that allow us to retain increasing equity in the long-term value of our pipeline. Our strategic partnerships with GlaxoSmithKline, Bristol-Myers Squibb Company and Symphony Capital exemplify how our innovative approach to drug development is enabling us to create value for our shareholders and patients. Based in South San Francisco, California, Exelixis has over 550 dedicated employees who share a commitment to making a positive difference in the lives of patients with cancer and other serious diseases. |
|